A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Recent research out of Cornell University showed that GLP-1 users' grocery bills have been reduced by as much as 8.6% — with ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...